INTRODUCTION AND OBJECTIVES:
The objective was to analyze the association between hospital competition and mortality and emergency room (ER) admission among prostate cancer patients with localized or advanced disease stage.
METHODS: This was a population-based cohort study of Surveillance, Epidemiological, and End Results-Medicare (SEERMedicare) data from 1995-2013, linked with AMA and AHA data. Eligible patients were men 66 years or older with localized or advanced stage prostate cancer at diagnosis. The HirschmanHerfindahl index (HHI) was computed for all serving hospitals. For each hospital, we calculated the number of competitors (number of hospitals situated within the predicted radius) and HHI. Outcomes were overall and prostate cancer-specific survival and ER admissions. We used Cox regression for survival, and Poisson (zero inflated) models for count data.
RESULTS: In our cohort, 210,602 patients had localized disease stage, and 43,065 patients had advanced stage. For both localized and advanced stage groups, age, race and ethnicity, geographic region, comorbidity, socio-economic status, and first treatment differed by hospital competition (high competition vs. low competition). Hospitals within high competition area were more likely to perform surgery, whereas hospitals within low competition area were more likely to perform radiation therapy. Among localized disease patients, low hospital competition was associated with higher hazard of overall mortality (HR[1.08, 95% CI[1.07 -1.10) and prostate cancer-specific mortality (HR[1.13, 95% CI[1.09 -1.17) and higher odds of ER visits (OR[1.13, 95% CI[1.11 -1.15). For advanced stage patients, low hospital competition was associated with higher hazard of overall mortality (HR[1.11, 95% CI[1.08 -1.15) and prostate cancer-specific death (HR[1.15, 95% CI[1.09 -1.18) and higher odds of ER visits (OR[1.16, .
CONCLUSIONS: This novel study showed that higher hospital competition is associated with reduced mortality and lower ER admission among patients with localized or advanced stage prostate cancer. Especially for advanced prostate cancer, switching patients from low to high competition hospitals may reduce overall mortality and ER visits. Additional research is needed to identify the mechanism through which hospital competition affects prostate cancer care outcomes. States between 2004-2015 using the National Cancer Database (NCDB). Institutions were ranked according to the proportion of Black and Hispanic patients treated at a given institution, and the top decile institutions were defined as MSH. We used multivariable analyses to characterize the association between MSH and three endpoints: receipt of definitive treatment, time to definitive treatment, and receipt of androgen deprivation therapy in young ( 65 years) and healthy (no comorbidity) men treated with external beam radiation therapy.
Source of
RESULTS: 162 and 1168 hospitals were defined as MSH and non-MSH, respectively. In multivariable analyses, MSH was associated with decreased odds of receiving definitive treatment (Adjusted Odds Ratio [AOR] 0.73 95%-CI: 0.62 -0.85, p<0.001). The adjusted mean time to treatment was significantly longer in MSHs compared to non-MSHs (4.9days, standard error 2.2; p[0.024). Among young and healthy men, there was no association between treatment at MSH and receipt of androgen deprivation therapy in conjunction with external beam radiation (AOR 0.90; 95%-CI: 0.75 -1.09, p[0.291).
CONCLUSIONS: Treatment at MSH was associated with lower odds of receiving definitive therapy and longer time to definitive therapy for localized intermediate-and high-risk PCa, despite adjustment for race. This suggests that some of the racial disparities in PCa may be explained by the sites at which racial/ ethnic minorities receive care.
